CompletedNot Applicable

Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study

United States50 participantsStarted 2015-06

Plain-language summary

To determine the persistence of protective antibody levels for subjects who seroconverted after vaccination with NmVac4-A/C/Y/W-135-DT™ Participants in trial # JN-NM-002, who seroconverted for serogroups A and C will be contacted and asked to provide a blood sample at 12-24 months after vaccination with NmVac4-A/C/Y/W-135-DT. Serum Bactericidal Assays will be performed to evaluated duration of protective antibody titer for NmVac4-A/C/Y/W-135-DT for all four serogroups. To determine if subjects who seroconverted with lower titers retain protective levels of antibody (titer ≥:8) at 12-24 months after vaccination.

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Willing and able to give informed consent * Participant in trial JN-NM-002 * Seroconverted in trial JN-NM-002 for both serogroups A and C Exclusion Criteria: * Chronic medication use or medical history that, in the opinion of the Investigator, may impact the quality of the sample or safety of the subject

What they're measuring

Antibody titer

Timeframe: 12-24 months after vaccination in study JN-NM-002

Trial details

NCT IDNCT02500511

SponsorJN-International Medical Corporation

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2015-08

View on ClinicalTrials.gov More Meningococcal Meningitis trials